Article title: Repurposing nirogacestat, a gamma secretase enzyme inhibitor in desmoid tumors
Authors: Ghazal Tansir, Sameer Rastogi and Mrinal M. Gounder
Journal: Future Oncology
DOI: https://doi.org/10.1080/14796694.2025.2550826
When this article was initially published online, the sentences below were incorrect. These have now been corrected as shown below, and the article has been republished online.
1. Page 1 Abstract:
Original: Nirogacestat received Food and Drug Administration (FDA) approval in November 2023 for management of progressive, unresectable, recurrent, or refractory DT.
Corrected: Nirogacestat received Food and Drug Administration (FDA) approval in November 2023 and European Commission approval in August 2025 for adults with progressing desmoid tumors (DT) who require systemic treatment.
2. Page 5, Column 2, paragraph 1:
Original: Of the 6 whose ovarian dysfunction was unresolved, 5 (29%) were still on nirogacestat therapy and follow-up information for the remaining 2 (7%) was not available.
Corrected: Of the 6 whose ovarian dysfunction was unresolved, 4 (29%) were still on nirogacestat therapy and follow-up information for the remaining 2 (7%) was not available.
3. Page 6 Column 1: paragraph 3:
Original: While reimbursement options are available from insurance facilities in the Unites States, nirogacestat has not yet obtained approval in the European Union and India.
Corrected: Reimbursement options are available from insurance facilities in the Unites States. Nirogacestat has been approved in the United States and the European Union and has not yet obtained approval in India.